A survey of open questions in adaptive therapy : bridging mathematics and clinical translation
West, Jeffrey; Adler, Fred; Gallaher, Jill; Strobl, Maximilian; Brady-Nicholls, Renee; Brown, Joel S.; Robertson-Tessi, Mark; Kim, Eun Jung; Noble, Robert; Viossat, Yannick; Basanta, David; Anderson, Alexander R. A. (2022), A survey of open questions in adaptive therapy : bridging mathematics and clinical translation. https://basepub.dauphine.psl.eu/handle/123456789/23745
View/ Open
Type
Document de travail / Working paperDate
2022Series title
Cahier de recherche CEREMADE, Université Paris Dauphine-PSLPublished in
Paris
Pages
27
Metadata
Show full item recordAuthor(s)
West, JeffreyH. Lee Moffitt Cancer Center and Research Institute
Adler, Fred
Department of Mathematics - University of Utah
Gallaher, Jill
H. Lee Moffitt Cancer Center and Research Institute
Strobl, Maximilian
H. Lee Moffitt Cancer Center and Research Institute
Brady-Nicholls, Renee
H. Lee Moffitt Cancer Center and Research Institute
Brown, Joel S.
H. Lee Moffitt Cancer Center and Research Institute
Robertson-Tessi, Mark
H. Lee Moffitt Cancer Center and Research Institute
Kim, Eun Jung

Korea Advanced Institute of Science and Technology [KAIST]
Noble, Robert
City University of London
Viossat, Yannick
CEntre de REcherches en MAthématiques de la DEcision [CEREMADE]
Basanta, David
H. Lee Moffitt Cancer Center and Research Institute
Anderson, Alexander R. A.
H. Lee Moffitt Cancer Center and Research Institute
Abstract (EN)
Adaptive therapy is a dynamic cancer treatment protocol that updates (or "adapts") treatment decisions in anticipation of evolving tumor dynamics. This broad term encompasses many possible dynamic treatment protocols of patient-specific dose modulation or dose timing. Adaptive therapy maintains high levels of tumor burden to benefit from the competitive suppression of treatment-sensitive subpopulations on treatment-resistant subpopulations. This evolution-based approach to cancer treatment has been integrated into several ongoing or planned clinical trials, including treatment of metastatic castrate resistant prostate cancer, ovarian cancer, and BRAF-mutant melanoma. In the previous few decades, experimental and clinical investigation of adaptive therapy has progressed synergistically with mathematical and computational modeling. In this work, we discuss 11 open questions in cancer adaptive therapy mathematical modeling. The questions are split into three sections: 1) the necessary components of mathematical models of adaptive therapy 2) design and validation of dosing protocols, and 3) challenges and opportunities in clinical translation.Related items
Showing items related by title and author.
-
Strobl, Maximilian A.R.; West, Jeffrey; Viossat, Yannick; Damaghi, Mehdi; Robertson-Tessi, Mark; Brown, Joel; Gatenby, R.; Maini, P. K.; Anderson, A. R. A. (2021) Article accepté pour publication ou publié
-
Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer Cunningham, Jessica; Thuijsman, Frank; Peeters, Ralf; Viossat, Yannick; Brown, Joel; Gatenby, Robert; Staňková, K. (2020) Article accepté pour publication ou publié
-
Crowston, Robert; Fellows, Michael R.; Gutin, Gregory; Jones, Mark; Kim, Eun Jung; Rosamond, Frances; Rusza, Imre Z.; Thomassé, Stéphan; Yeo, Anders (2014) Article accepté pour publication ou publié
-
Kim, Eun Jung; Langer, Alexander; Paul, Christophe; Reidl, Felix; Rossmanith, Peter; Sau Valls, Ignasi (2016) Article accepté pour publication ou publié
-
Kim, Eun Jung; Langer, Alexander; Paul, Christophe; Reidl, Felix; Rossmanith, Peter; Sau Valls, Ignasi; Sikdar, Somnath (2013-07) Communication / Conférence